drugset

drugset / Trial / NCT00405249

Safety Study of Elvucitabine in HIV-1 Subjects

NCT00405249 ↗

Phase 2 Completed 5 enrolled Thomas Jefferson University

RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.

Timeline

Start: 2006-09
Primary completion: 2006-11
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elvucitabine	Small molecule	—	—

Indications